Bambusa Therapeutics: Oversubscribed Series A-2 Round Raised To Advance Next-Generation Bispecific Pipeline
By Amit Chowdhry ● Yesterday at 3:38 PM
Bambusa Therapeutics has completed an oversubscribed Series A-2 financing round at a significant valuation increase, marking a major milestone as the Boston-based biotechnology company accelerates the development of its next wave of bispecific antibody programs. The clinical-stage company, which focuses on advancing transformative therapies for immunology and inflammation, secured expanded participation from all existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners, Salvia, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma, an investment platform controlled by KKR. Their sustained support reflects increased confidence in the company’s bispecific platform, executional strength, and growing clinical momentum.